Michael M. Abecassis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Michael M. Abecassis has a total of 334 co-authors. Here are the top co-authors by number of shared publications:
Laura Kulik
Department of Medicine, Division of Hepatology, Northwestern University, Chicago, Illinois
8 shared publications- Riad Salem
Department of Radiology, Section of Vascular and Interventional Radiology, Northwestern University, Chicago, USA
8 shared publications - John J. Friedewald
Comprehensive Transplant Center, Northwestern University, Chicago, IL, USA
6 shared publications Robert J. Lewandowski
Department of Radiology, Section of Interventional Radiology, Northwestern Memorial Hospital, Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois
6 shared publications- Ahmed Gabr
Department of Radiology, Section of Interventional Radiology, Northwestern University, Chicago, IL, USA
5 shared publications Bartley Thornburg
Department of Radiology, Section of Interventional Radiology, Northwestern Memorial Hospital, Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois
5 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 12 September 2021
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (2) , 532-540
Donor-derived cell-free DNA levels predict graft injury in liver transplant recipients
- 12 September 2021
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (2) , 532-540
Top Cited PapersOpen AccessDonor-derived cell-free DNA levels predict graft injury in liver transplant recipients
- Open Access
- 18 September 2020
- Published by Elsevier in American Journal of Transplantation
- Vol. 21 (3) , 1346-1347
Letter to the AJT Editor re: Puttarajappa et al (doi:10.1111/ajt.16150)
- 18 September 2020
- Published by Elsevier in American Journal of Transplantation
- Vol. 21 (3) , 1346-1347
Open AccessLetter to the AJT Editor re: Puttarajappa et al (doi:10.1111/ajt.16150)
- Open Access
- 17 August 2020
- Published by Elsevier in American Journal of Transplantation
- Vol. 21 (2) , 515-524
Acute murine cytomegalovirus disrupts established transplantation tolerance and causes recipient allo-sensitization
- 17 August 2020
- Published by Elsevier in American Journal of Transplantation
- Vol. 21 (2) , 515-524
Open AccessAcute murine cytomegalovirus disrupts established transplantation tolerance and causes recipient allo-sensitization
- Open Access
- 24 February 2020
- Published by Elsevier in American Journal of Transplantation
- Vol. 20 (6) , 1495-1502
Use of biomarkers to improve immunosuppressive drug development and outcomes in renal organ transplantation: A meeting report
- 24 February 2020
- Published by Elsevier in American Journal of Transplantation
- Vol. 20 (6) , 1495-1502
Open AccessUse of biomarkers to improve immunosuppressive drug development and outcomes in renal organ transplantation: A meeting report
- Open Access
- 1 December 2019
- Published by Microbiology Society in Journal of General Virology
- Vol. 100 (12) , 1680-1694
A novel murine model of differentiation-mediated cytomegalovirus reactivation from latently infected bone marrow haematopoietic cells
CD34+ myeloid lineage progenitor cells are an important reservoir of latent human cytomegalovirus (HCMV), and differentiation to macrophages or dendritic cells (DCs) is known to cause reactivation of latent virus. Due to its species-specificity, murine models have been used to study mouse CMV (MCMV) latency and reactivation in vivo. While previous studies have shown that MCMV genomic DNA can be detected in the bone marrow (BM) of latently infected mice, the identity of these cells has not been defined. Therefore, we sought to identify and enrich for cellular sites of MCMV latency in the BM haematopoietic system, and to explore the potential for establishing an in vitro model for reactivation of latent MCMV. We studied the kinetics and cellular characteristics of acute infection and establishment of latency in the BM of mice. We found that while MCMV can infect a broad range of haematopoietic BM cells (BMCs), latent virus is only detectable in haematopoietic stem cells (HSCs), myeloid progenitor cells, monocytes and DC-enriched cell subsets. Using three separate approaches, MCMV reactivation was detected in association with differentiation into DC-enriched BMCs cultured in the presence of granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin 4 (IL-4) followed by lipopolysaccharide (LPS) treatment. In summary, we have defined the kinetics and cellular profile of MCMV infection followed by the natural establishment of latency in vivo in the mouse BM haematopoietic system, including the haematopoietic phenotypes of cells that are permissive to acute infection, establish and harbour detectable latent virus, and can be stimulated to reactivate following DC enrichment and differentiation, followed by treatment with LPS.
- 1 December 2019
- Published by Microbiology Society in Journal of General Virology
- Vol. 100 (12) , 1680-1694
Open AccessA novel murine model of differentiation-mediated cytomegalovirus reactivation from latently infected bone marrow haematopoietic cells
CD34+ myeloid lineage progenitor cells are an important reservoir of latent human cytomegalovirus (HCMV), and differentiation to macrophages or dendritic cells (DCs) is known to cause reactivation of latent virus. Due to its species-specificity, murine models have been used to study mouse CMV (MCMV) latency and reactivation in vivo. While previous studies have shown that MCMV genomic DNA can be detected in the bone marrow (BM) of latently infected mice, the identity of these cells has not been defined. Therefore, we sought to identify and enrich for cellular sites of MCMV latency in the BM haematopoietic system, and to explore the potential for establishing an in vitro model for reactivation of latent MCMV. We studied the kinetics and cellular characteristics of acute infection and establishment of latency in the BM of mice. We found that while MCMV can infect a broad range of haematopoietic BM cells (BMCs), latent virus is only detectable in haematopoietic stem cells (HSCs), myeloid progenitor cells, monocytes and DC-enriched cell subsets. Using three separate approaches, MCMV reactivation was detected in association with differentiation into DC-enriched BMCs cultured in the presence of granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin 4 (IL-4) followed by lipopolysaccharide (LPS) treatment. In summary, we have defined the kinetics and cellular profile of MCMV infection followed by the natural establishment of latency in vivo in the mouse BM haematopoietic system, including the haematopoietic phenotypes of cells that are permissive to acute infection, establish and harbour detectable latent virus, and can be stimulated to reactivate following DC enrichment and differentiation, followed by treatment with LPS.
- Open Access
- 4 April 2019
- Published by Elsevier in American Journal of Transplantation
- Vol. 19 (9) , 2421-2433
A clinically relevant murine model unmasks a “two-hit” mechanism for reactivation and dissemination of cytomegalovirus after kidney transplant
- 4 April 2019
- Published by Elsevier in American Journal of Transplantation
- Vol. 19 (9) , 2421-2433
Open AccessA clinically relevant murine model unmasks a “two-hit” mechanism for reactivation and dissemination of cytomegalovirus after kidney transplant
- Open Access
- 1 April 2019
- Published by Elsevier in Transplantation Proceedings
- Vol. 51 (3) , 729-733
Investigator Assessment of the Utility of the TruGraf Molecular Diagnostic Test in Clinical Practice
- 1 April 2019
- Published by Elsevier in Transplantation Proceedings
- Vol. 51 (3) , 729-733
Open AccessInvestigator Assessment of the Utility of the TruGraf Molecular Diagnostic Test in Clinical Practice
- Open Access
- 26 February 2019
- Published by Elsevier in American Journal of Transplantation
- Vol. 19 (7) , 2141-2142
Clinical implications for the use of a biomarker for subclinical rejection – Conflating arguments cause a disconnection between the premise and the conclusion
- 26 February 2019
- Published by Elsevier in American Journal of Transplantation
- Vol. 19 (7) , 2141-2142
Open AccessClinical implications for the use of a biomarker for subclinical rejection – Conflating arguments cause a disconnection between the premise and the conclusion
- Top Cited PapersOpen Access
- 9 July 2018
- Published by Elsevier in American Journal of Transplantation
- Vol. 19 (1) , 98-109
Development and clinical validity of a novel blood-based molecular biomarker for subclinical acute rejection following kidney transplant
- 9 July 2018
- Published by Elsevier in American Journal of Transplantation
- Vol. 19 (1) , 98-109
Top Cited PapersOpen AccessDevelopment and clinical validity of a novel blood-based molecular biomarker for subclinical acute rejection following kidney transplant
- Open Access
- 12 June 2018
- Published by Elsevier in American Journal of Transplantation
- Vol. 18 (9) , 2368-2369
Response to “Shifting the conversation on outcomes reporting”
- 12 June 2018
- Published by Elsevier in American Journal of Transplantation
- Vol. 18 (9) , 2368-2369
Open AccessResponse to “Shifting the conversation on outcomes reporting”